Interstitial Lung Disease clinical trials at UCSD
2 in progress, 1 open to eligible people
Showing trials for
MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
open to eligible people ages 18 years and up
The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.
La Jolla, California and other locations
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, not currently recruiting here
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
La Jolla, California and other locations
Our lead scientists for Interstitial Lung Disease research studies include Gordon Yung, MD.
Last updated: